Background: A novel human inhibitor of apoptosis protein (IAP) family member termed Livin was identified, containing a single baculoviral IAP repeat (BIR) domain and a COOH-terminal RING finger domain. It Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits caspase-3 and proteolytic activation of pro-caspase-9. Isoform 1 blocks staurosporine-induced apoptosis and isoform 2 blocks etoposide-induced apoptosis. Livin binds to caspase-9. Interaction with SMAC via the BIR domain disrupts binding to caspase-9 and apoptotic suppressor activity. Interacts with TAB1. In vitro, interacts with caspase-3 and caspase-7 via its BIR domain. Belongs to the IAP family.
Description: Rabbit polyclonal to Livin
Immunogen: KLH conjugated synthetic peptide derived from Livin
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 33 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
